ID   GALE_HUMAN              Reviewed;         348 AA.
AC   Q14376; A0A024RAH5; B3KQ39; Q38G75; Q86W41; Q9BVE3; Q9UJB4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 2.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=UDP-glucose 4-epimerase {ECO:0000303|PubMed:22654673};
DE            EC=5.1.3.2 {ECO:0000269|PubMed:22654673};
DE   AltName: Full=Galactowaldenase;
DE   AltName: Full=UDP-N-acetylgalactosamine 4-epimerase {ECO:0000303|PubMed:22654673};
DE            Short=UDP-GalNAc 4-epimerase {ECO:0000303|PubMed:22654673};
DE   AltName: Full=UDP-N-acetylglucosamine 4-epimerase {ECO:0000303|PubMed:22654673};
DE            Short=UDP-GlcNAc 4-epimerase {ECO:0000303|PubMed:22654673};
DE            EC=5.1.3.7 {ECO:0000269|PubMed:22654673};
DE   AltName: Full=UDP-galactose 4-epimerase {ECO:0000303|PubMed:22654673};
GN   Name=GALE {ECO:0000312|HGNC:HGNC:4116};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-180.
RX   PubMed=8593531; DOI=10.1006/bmme.1995.1048;
RA   Daude N., Gallaher T.K., Zeschnigk M., Starzinski-Powitz A.,
RA   Petry K.G., Haworth I.S., Reichardt J.K.V.;
RT   "Molecular cloning, characterization, and mapping of a full-length
RT   cDNA encoding human UDP-galactose 4'-epimerase.";
RL   Biochem. Mol. Med. 56:1-7(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS EDG GLU-90; GLY-103;
RP   ARG-257; MET-313 AND GLU-319.
RX   PubMed=9538513; DOI=10.1006/mgme.1997.2645;
RA   Maceratesi P., Daude N., Dallapiccola B., Novelli G., Allen R.,
RA   Okano Y., Reichardt J.K.V.;
RT   "Human UDP-galactose 4'epimerase (GALE) gene and identification of
RT   five missense mutations in patients with epimerase deficiency
RT   galactosemia.";
RL   Mol. Genet. Metab. 63:26-30(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=16385452; DOI=10.1086/498985;
RA   Openo K.K., Schulz J.M., Vargas C.A., Orton C.S., Epstein M.P.,
RA   Schnur R.E., Scaglia F., Berry G.T., Gottesman G.S., Ficicioglu C.,
RA   Slonim A.E., Schroer R.J., Yu C., Rangel V.E., Keenan J., Lamance K.,
RA   Fridovich-Keil J.L.;
RT   "Epimerase-deficiency galactosemia is not a binary condition.";
RL   Am. J. Hum. Genet. 78:89-102(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Colon, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=22654673; DOI=10.1371/journal.pgen.1002721;
RA   Daenzer J.M., Sanders R.D., Hang D., Fridovich-Keil J.L.;
RT   "UDP-galactose 4'-epimerase activities toward UDP-Gal and UDP-GalNAc
RT   play different roles in the development of Drosophila melanogaster.";
RL   PLoS Genet. 8:E1002721-E1002721(2012).
RN   [10]
RP   FUNCTION.
RX   PubMed=23732289; DOI=10.1016/j.gene.2013.05.027;
RA   Timson D.J., Lindert S.;
RT   "Comparison of dynamics of wildtype and V94M human UDP-galactose 4-
RT   epimerase-A computational perspective on severe epimerase-deficiency
RT   galactosemia.";
RL   Gene 526:318-324(2013).
RN   [11]
RP   MUTAGENESIS OF SER-132; TYR-157 AND CYS-307.
RX   PubMed=15175331; DOI=10.1074/jbc.M405005200;
RA   Schulz J.M., Watson A.L., Sanders R., Ross K.L., Thoden J.B.,
RA   Holden H.M., Fridovich-Keil J.L.;
RT   "Determinants of function and substrate specificity in human UDP-
RT   galactose 4'-epimerase.";
RL   J. Biol. Chem. 279:32796-32803(2004).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH NAD AND THE
RP   SUBSTRATE UDP-D-GLUCOSE, AND SUBUNIT.
RX   PubMed=10801319; DOI=10.1021/bi000215l;
RA   Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M.;
RT   "Crystallographic evidence for Tyr 157 functioning as the active site
RT   Proton acceptor in human UDP-galactose 4-epimerase.";
RL   Biochemistry 39:5691-5701(2000).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH NAD AND THE
RP   SUBSTRATE UDP-N-ACETYL-ALPHA-D-GLUCOSAMINE.
RX   PubMed=11279032; DOI=10.1074/jbc.M100220200;
RA   Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M.;
RT   "Human UDP-galactose 4-epimerase. Accommodation of UDP-N-
RT   acetylglucosamine within the active site.";
RL   J. Biol. Chem. 276:15131-15136(2001).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF VARIANT EDG MET-94 IN
RP   COMPLEXES WITH NAD AND THE SUBSTRATE ANALOGS UDP-D-GALACTOSE;
RP   UDP-N-ACETYL-ALPHA-D-GLUCOSAMINE; UDP-D-GLUCOSE.
RX   PubMed=11279193; DOI=10.1074/jbc.M101304200;
RA   Thoden J.B., Wohlers T.M., Fridovich-Keil J.L., Holden H.M.;
RT   "Molecular basis for severe epimerase deficiency galactosemia. X-ray
RT   structure of the human V94m-substituted UDP-galactose 4-epimerase.";
RL   J. Biol. Chem. 276:20617-20623(2001).
RN   [16]
RP   VARIANTS EDG SER-34 AND PRO-183, AND VARIANT VAL-180.
RX   PubMed=9326324; DOI=10.1086/515517;
RA   Quimby B.B., Alano A., Almashanu S., Desandro A.M., Cowan T.M.,
RA   Fridovich-Keil J.L.;
RT   "Characterization of two mutations associated with epimerase-
RT   deficiency galactosemia, by use of a yeast expression system for human
RT   UDP-galactose-4-epimerase.";
RL   Am. J. Hum. Genet. 61:590-598(1997).
RN   [17]
RP   VARIANT EDG MET-94, AND CHARACTERIZATION OF VARIANTS EDG GLU-90;
RP   MET-94; GLY-103 AND MET-313.
RX   PubMed=9973283; DOI=10.1086/302263;
RA   Wohlers T.M., Christacos N.C., Harreman M.T., Fridovich-Keil J.L.;
RT   "Identification and characterization of a mutation, in the human UDP-
RT   galactose-4-epimerase gene, associated with generalized epimerase-
RT   deficiency galactosemia.";
RL   Am. J. Hum. Genet. 64:462-470(1999).
RN   [18]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION OF VARIANT MET-94.
RX   PubMed=11117433; DOI=10.1023/A:1005682913784;
RA   Wohlers T.M., Fridovich-Keil J.L.;
RT   "Studies of the V94M-substituted human UDPgalactose-4-epimerase enzyme
RT   associated with generalized epimerase-deficiency galactosaemia.";
RL   J. Inherit. Metab. Dis. 23:713-729(2000).
RN   [19]
RP   VARIANTS EDG SER-34; GLU-90; MET-94; GLY-103; PRO-183; ARG-257;
RP   MET-313; GLU-319 AND HIS-335.
RX   PubMed=11903335; DOI=10.1034/j.1399-0004.2001.600505.x;
RA   Henderson J.M., Huguenin S.M., Cowan T.M., Fridovich-Keil J.L.;
RT   "A PCR-based method for detecting known mutations in the human UDP
RT   galactose-4'-epimerase gene associated with epimerase-deficiency
RT   galactosemia.";
RL   Clin. Genet. 60:350-355(2001).
RN   [20]
RP   BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS EDG
RP   SER-34; GLU-90; MET-94; GLY-103; PRO-183; ARG-257; MET-313; GLU-319
RP   AND HIS-335, AND SUBUNIT.
RX   PubMed=16302980; DOI=10.1111/j.1742-4658.2005.05017.x;
RA   Timson D.J.;
RT   "Functional analysis of disease-causing mutations in human UDP-
RT   galactose 4-epimerase.";
RL   FEBS J. 272:6170-6177(2005).
RN   [21]
RP   VARIANTS EDG VAL-25; CYS-40; GLU-69; LYS-165; TRP-169; TRP-239;
RP   ASP-302 AND HIS-335.
RX   PubMed=16301867; DOI=10.1097/01.gim.0000194023.27802.2d;
RA   Park H.-D., Park K.U., Kim J.Q., Shin C.H., Yang S.W., Lee D.H.,
RA   Song Y.-H., Song J.;
RT   "The molecular basis of UDP-galactose-4-epimerase (GALE) deficiency
RT   galactosemia in Korean patients.";
RL   Genet. Med. 7:646-649(2005).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS EDG ARG-257 AND GLU-319.
RX   PubMed=15639193; DOI=10.1016/j.ymgme.2004.09.003;
RA   Wasilenko J., Lucas M.E., Thoden J.B., Holden H.M.,
RA   Fridovich-Keil J.L.;
RT   "Functional characterization of the K257R and G319E-hGALE alleles
RT   found in patients with ostensibly peripheral epimerase deficiency
RT   galactosemia.";
RL   Mol. Genet. Metab. 84:32-38(2005).
CC   -!- FUNCTION: Catalyzes two distinct but analogous reactions: the
CC       reversible epimerization of UDP-glucose to UDP-galactose and the
CC       reversible epimerization of UDP-N-acetylglucosamine to UDP-N-
CC       acetylgalactosamine. The reaction with UDP-Gal plays a critical
CC       role in the Leloir pathway of galactose catabolism in which
CC       galactose is converted to the glycolytic intermediate glucose 6-
CC       phosphate. It contributes to the catabolism of dietary galactose
CC       and enables the endogenous biosynthesis of both UDP-Gal and UDP-
CC       GalNAc when exogenous sources are limited. Both UDP-sugar
CC       interconversions are important in the synthesis of glycoproteins
CC       and glycolipids. {ECO:0000269|PubMed:22654673,
CC       ECO:0000303|PubMed:23732289}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-glucose = UDP-alpha-D-galactose.
CC       {ECO:0000269|PubMed:22654673}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-glucosamine = UDP-N-
CC       acetyl-alpha-D-galactosamine. {ECO:0000269|PubMed:22654673}.
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC         Evidence={ECO:0000269|PubMed:10801319,
CC         ECO:0000269|PubMed:22654673, ECO:0000303|PubMed:11279032,
CC         ECO:0000303|PubMed:11279193};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=69 uM for UDP-galactose (at 37 degrees Celsius and pH 8.8)
CC         {ECO:0000269|PubMed:11117433, ECO:0000269|PubMed:16302980};
CC         Vmax=1.22 mmol/min/mg enzyme with UDP-galactose as substrate
CC         {ECO:0000269|PubMed:11117433, ECO:0000269|PubMed:16302980};
CC   -!- PATHWAY: Carbohydrate metabolism; galactose metabolism.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:10801319,
CC       ECO:0000269|PubMed:16302980}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-750057, EBI-750057;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14376-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14376-2; Sequence=VSP_056822;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC   -!- DISEASE: Epimerase-deficiency galactosemia (EDG) [MIM:230350]:
CC       Clinical features include early-onset cataracts, liver damage,
CC       deafness and mental retardation. There are two clinically distinct
CC       forms of EDG. (1) A benign, or 'peripheral' form with no
CC       detectable GALE activity in red blood cells and characterized by
CC       mild symptoms. Some patients may suffer no symptoms beyond raised
CC       levels of galactose-1-phosphate in the blood. (2) A much rarer
CC       'generalized' form with undetectable levels of GALE activity in
CC       all tissues and resulting in severe features such as restricted
CC       growth and mental development. {ECO:0000269|PubMed:11279193,
CC       ECO:0000269|PubMed:11903335, ECO:0000269|PubMed:15639193,
CC       ECO:0000269|PubMed:16301867, ECO:0000269|PubMed:16302980,
CC       ECO:0000269|PubMed:9326324, ECO:0000269|PubMed:9538513,
CC       ECO:0000269|PubMed:9973283}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Contrary to the human enzyme, the E.coli ortholog
CC       (AC P09147) does not catalyze the epimerization of UDP-N-
CC       acetylglucosamine to UDP-N-acetylgalactosamine. Compared to the
CC       E.coli enzyme, the sugar-binding pocket of the active site is 15%
CC       larger for the human enzyme, making it possible to accommodate the
CC       acetyl group. {ECO:0000269|PubMed:11279032}.
CC   -!- SIMILARITY: Belongs to the NAD(P)-dependent epimerase/dehydratase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=EAW95083.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95084.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95086.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95090.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95091.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95092.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=EAW95093.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L41668; AAB86498.1; -; mRNA.
DR   EMBL; AF022382; AAC39645.1; -; Genomic_DNA.
DR   EMBL; DQ233667; ABB04109.1; -; Genomic_DNA.
DR   EMBL; DQ233668; ABB04110.1; -; mRNA.
DR   EMBL; AK057302; BAG51901.1; -; mRNA.
DR   EMBL; AK314397; BAG37021.1; -; mRNA.
DR   EMBL; AL031295; CAB40159.1; -; Genomic_DNA.
DR   EMBL; CH471134; EAW95083.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95084.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95086.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95090.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95091.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95092.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471134; EAW95093.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC001273; AAH01273.1; -; mRNA.
DR   EMBL; BC050685; AAH50685.2; -; mRNA.
DR   CCDS; CCDS242.1; -. [Q14376-1]
DR   RefSeq; NP_000394.2; NM_000403.3. [Q14376-1]
DR   RefSeq; NP_001008217.1; NM_001008216.1. [Q14376-1]
DR   RefSeq; NP_001121093.1; NM_001127621.1. [Q14376-1]
DR   UniGene; Hs.632380; -.
DR   PDB; 1EK5; X-ray; 1.80 A; A=1-348.
DR   PDB; 1EK6; X-ray; 1.50 A; A/B=1-348.
DR   PDB; 1HZJ; X-ray; 1.50 A; A/B=1-348.
DR   PDB; 1I3K; X-ray; 1.50 A; A/B=1-348.
DR   PDB; 1I3L; X-ray; 1.50 A; A/B=1-348.
DR   PDB; 1I3M; X-ray; 1.50 A; A/B=1-348.
DR   PDB; 1I3N; X-ray; 1.50 A; A/B=1-348.
DR   PDBsum; 1EK5; -.
DR   PDBsum; 1EK6; -.
DR   PDBsum; 1HZJ; -.
DR   PDBsum; 1I3K; -.
DR   PDBsum; 1I3L; -.
DR   PDBsum; 1I3M; -.
DR   PDBsum; 1I3N; -.
DR   ProteinModelPortal; Q14376; -.
DR   SMR; Q14376; -.
DR   BioGrid; 108855; 21.
DR   IntAct; Q14376; 2.
DR   MINT; MINT-5001272; -.
DR   STRING; 9606.ENSP00000363621; -.
DR   BindingDB; Q14376; -.
DR   ChEMBL; CHEMBL5843; -.
DR   DrugBank; DB03501; Galactose-uridine-5'-diphosphate.
DR   DrugBank; DB03095; Tetramethylammonium Ion.
DR   DrugBank; DB01861; Uridine diphosphate glucose.
DR   DrugBank; DB02196; Uridine-Diphosphate-N-Acetylgalactosamine.
DR   DrugBank; DB03397; Uridine-Diphosphate-N-Acetylglucosamine.
DR   iPTMnet; Q14376; -.
DR   PhosphoSitePlus; Q14376; -.
DR   SwissPalm; Q14376; -.
DR   BioMuta; GALE; -.
DR   DMDM; 68056598; -.
DR   EPD; Q14376; -.
DR   PaxDb; Q14376; -.
DR   PeptideAtlas; Q14376; -.
DR   PRIDE; Q14376; -.
DR   TopDownProteomics; Q14376-1; -. [Q14376-1]
DR   DNASU; 2582; -.
DR   Ensembl; ENST00000374497; ENSP00000363621; ENSG00000117308. [Q14376-1]
DR   Ensembl; ENST00000617979; ENSP00000483375; ENSG00000117308. [Q14376-1]
DR   GeneID; 2582; -.
DR   KEGG; hsa:2582; -.
DR   UCSC; uc001bhv.2; human. [Q14376-1]
DR   CTD; 2582; -.
DR   DisGeNET; 2582; -.
DR   GeneCards; GALE; -.
DR   GeneReviews; GALE; -.
DR   HGNC; HGNC:4116; GALE.
DR   HPA; HPA007340; -.
DR   MalaCards; GALE; -.
DR   MIM; 230350; phenotype.
DR   MIM; 606953; gene.
DR   neXtProt; NX_Q14376; -.
DR   OpenTargets; ENSG00000117308; -.
DR   Orphanet; 308473; Erythrocyte galactose epimerase deficiency.
DR   Orphanet; 308487; Generalized galactose epimerase deficiency.
DR   PharmGKB; PA28531; -.
DR   eggNOG; KOG1371; Eukaryota.
DR   eggNOG; COG1087; LUCA.
DR   GeneTree; ENSGT00530000063128; -.
DR   HOGENOM; HOG000168001; -.
DR   HOVERGEN; HBG001396; -.
DR   InParanoid; Q14376; -.
DR   KO; K01784; -.
DR   OMA; CGCKVYN; -.
DR   OrthoDB; EOG091G0ACI; -.
DR   PhylomeDB; Q14376; -.
DR   TreeFam; TF105800; -.
DR   BioCyc; MetaCyc:HS04117-MONOMER; -.
DR   BRENDA; 5.1.3.2; 2681.
DR   Reactome; R-HSA-70370; Galactose catabolism.
DR   SABIO-RK; Q14376; -.
DR   UniPathway; UPA00214; -.
DR   EvolutionaryTrace; Q14376; -.
DR   GenomeRNAi; 2582; -.
DR   PRO; PR:Q14376; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117308; -.
DR   CleanEx; HS_GALE; -.
DR   ExpressionAtlas; Q14376; baseline and differential.
DR   Genevisible; Q14376; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0003978; F:UDP-glucose 4-epimerase activity; IDA:UniProtKB.
DR   GO; GO:0003974; F:UDP-N-acetylglucosamine 4-epimerase activity; IEA:UniProtKB-EC.
DR   GO; GO:0019388; P:galactose catabolic process; IDA:UniProtKB.
DR   CDD; cd05247; UDP_G4E_1_SDR_e; 1.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR008089; Nuc_sugar_epim.
DR   InterPro; IPR005886; UDP_G4E.
DR   Pfam; PF16363; GDP_Man_Dehyd; 1.
DR   PRINTS; PR01713; NUCEPIMERASE.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR01179; galE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Carbohydrate metabolism;
KW   Complete proteome; Disease mutation; Galactose metabolism; Isomerase;
KW   NAD; Polymorphism; Reference proteome.
FT   CHAIN         1    348       UDP-glucose 4-epimerase.
FT                                /FTId=PRO_0000183189.
FT   NP_BIND      12     14       NAD. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   NP_BIND      33     37       NAD. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   NP_BIND      66     67       NAD. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   REGION      132    134       Substrate binding.
FT                                {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193,
FT                                ECO:0000303|PubMed:15175331}.
FT   REGION      185    187       Substrate binding.
FT                                {ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   REGION      206    208       Substrate binding.
FT                                {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   REGION      224    226       Substrate binding.
FT                                {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   REGION      300    303       Substrate binding.
FT                                {ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   ACT_SITE    157    157       Proton acceptor.
FT                                {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193,
FT                                ECO:0000303|PubMed:15175331}.
FT   BINDING      88     88       NAD; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   BINDING      92     92       NAD. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   BINDING     161    161       NAD. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   BINDING     185    185       NAD. {ECO:0000269|PubMed:10801319}.
FT   BINDING     239    239       Substrate. {ECO:0000269|PubMed:10801319,
FT                                ECO:0000269|PubMed:11279032,
FT                                ECO:0000269|PubMed:11279193}.
FT   VAR_SEQ       1     79       MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRG
FT                                GGSLPESLRRVQELTGRSVEFEEMDILDQGALQRLFKK ->
FT                                MSPLQ (in isoform 2).
FT                                /FTId=VSP_056822.
FT   VARIANT      25     25       A -> V (in EDG).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037733.
FT   VARIANT      34     34       N -> S (in EDG; peripheral; nearly normal
FT                                activity towards UDP-galactose;
FT                                dbSNP:rs121908046).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9326324}.
FT                                /FTId=VAR_002539.
FT   VARIANT      40     40       R -> C (in EDG; dbSNP:rs144492228).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037734.
FT   VARIANT      69     69       D -> E (in EDG).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037735.
FT   VARIANT      90     90       G -> E (in EDG; 800-fold decrease in UDP-
FT                                galactose epimerization activity;
FT                                dbSNP:rs28940882).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9538513,
FT                                ECO:0000269|PubMed:9973283}.
FT                                /FTId=VAR_002540.
FT   VARIANT      94     94       V -> M (in EDG; generalized; 30-fold
FT                                decrease in UDP-galactose epimerization
FT                                activity; 2-fold decrease in affinity for
FT                                UDP-galactose; 24% of normal activity
FT                                with respect to UDP-N-
FT                                acetylgalactosamine; dbSNP:rs121908047).
FT                                {ECO:0000269|PubMed:11117433,
FT                                ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9973283}.
FT                                /FTId=VAR_010058.
FT   VARIANT     103    103       D -> G (in EDG; 7-fold decrease in UDP-
FT                                galactose epimerization activity; very
FT                                mild decrease in activity towards UDP-N-
FT                                acetylgalactosamine; dbSNP:rs28940883).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9538513,
FT                                ECO:0000269|PubMed:9973283}.
FT                                /FTId=VAR_002541.
FT   VARIANT     165    165       E -> K (in EDG; dbSNP:rs528467258).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037736.
FT   VARIANT     169    169       R -> W (in EDG; dbSNP:rs137853859).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037737.
FT   VARIANT     180    180       A -> V (in dbSNP:rs3204468).
FT                                {ECO:0000269|PubMed:8593531,
FT                                ECO:0000269|PubMed:9326324}.
FT                                /FTId=VAR_002542.
FT   VARIANT     183    183       L -> P (in EDG; peripheral; 3-fold
FT                                decrease in UDP-galactose epimerization
FT                                activity; dbSNP:rs121908045).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9326324}.
FT                                /FTId=VAR_002543.
FT   VARIANT     239    239       R -> W (in EDG; dbSNP:rs137853860).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037738.
FT   VARIANT     257    257       K -> R (in EDG; 7-fold decrease in UDP-
FT                                galactose epimerization activity; does
FT                                not affect affinity for UDP-galactose;
FT                                dbSNP:rs28940884).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:15639193,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9538513}.
FT                                /FTId=VAR_002544.
FT   VARIANT     302    302       G -> D (in EDG; dbSNP:rs137853861).
FT                                {ECO:0000269|PubMed:16301867}.
FT                                /FTId=VAR_037739.
FT   VARIANT     313    313       L -> M (in EDG; 6-fold decrease in UDP-
FT                                galactose epimerization activity; very
FT                                mild decrease in activity towards UDP-N-
FT                                acetylgalactosamine; dbSNP:rs3180383).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9538513,
FT                                ECO:0000269|PubMed:9973283}.
FT                                /FTId=VAR_002545.
FT   VARIANT     319    319       G -> E (in EDG; nearly normal activity
FT                                towards UDP-galactose; mild impairment
FT                                under conditions of substrate limitation;
FT                                dbSNP:rs28940885).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:15639193,
FT                                ECO:0000269|PubMed:16302980,
FT                                ECO:0000269|PubMed:9538513}.
FT                                /FTId=VAR_002546.
FT   VARIANT     335    335       R -> H (in EDG; 2-fold decrease in UDP-
FT                                galactose epimerization activity;
FT                                dbSNP:rs368637540).
FT                                {ECO:0000269|PubMed:11903335,
FT                                ECO:0000269|PubMed:16301867,
FT                                ECO:0000269|PubMed:16302980}.
FT                                /FTId=VAR_037740.
FT   MUTAGEN     132    132       S->A: Loss of activity.
FT                                {ECO:0000269|PubMed:15175331}.
FT   MUTAGEN     157    157       Y->F: Loss of activity.
FT                                {ECO:0000269|PubMed:15175331}.
FT   MUTAGEN     307    307       C->Y: No effect on activity towards UDP-
FT                                galactose. Loss of activity towards UDP-
FT                                N-acetylgalactosamine.
FT                                {ECO:0000269|PubMed:15175331}.
FT   CONFLICT    293    293       P -> S (in Ref. 4; BAG51901).
FT   STRAND        3      8       {ECO:0000244|PDB:1EK6}.
FT   TURN          9     11       {ECO:0000244|PDB:1EK6}.
FT   HELIX        13     24       {ECO:0000244|PDB:1EK6}.
FT   STRAND       29     33       {ECO:0000244|PDB:1EK6}.
FT   STRAND       35     38       {ECO:0000244|PDB:1EK6}.
FT   STRAND       42     46       {ECO:0000244|PDB:1EK6}.
FT   HELIX        47     56       {ECO:0000244|PDB:1EK6}.
FT   STRAND       61     64       {ECO:0000244|PDB:1EK6}.
FT   HELIX        70     79       {ECO:0000244|PDB:1EK6}.
FT   STRAND       82     87       {ECO:0000244|PDB:1EK6}.
FT   HELIX        94     99       {ECO:0000244|PDB:1EK6}.
FT   HELIX       101    121       {ECO:0000244|PDB:1EK6}.
FT   STRAND      126    132       {ECO:0000244|PDB:1EK6}.
FT   HELIX       133    136       {ECO:0000244|PDB:1EK6}.
FT   STRAND      140    144       {ECO:0000244|PDB:1EK6}.
FT   HELIX       156    174       {ECO:0000244|PDB:1EK6}.
FT   STRAND      179    185       {ECO:0000244|PDB:1EK6}.
FT   STRAND      187    189       {ECO:0000244|PDB:1EK6}.
FT   STRAND      195    197       {ECO:0000244|PDB:1EK5}.
FT   STRAND      202    204       {ECO:0000244|PDB:1EK6}.
FT   HELIX       208    216       {ECO:0000244|PDB:1EK6}.
FT   STRAND      219    221       {ECO:0000244|PDB:1EK6}.
FT   STRAND      223    226       {ECO:0000244|PDB:1EK6}.
FT   STRAND      230    236       {ECO:0000244|PDB:1EK6}.
FT   STRAND      241    243       {ECO:0000244|PDB:1EK6}.
FT   HELIX       244    258       {ECO:0000244|PDB:1EK6}.
FT   TURN        259    261       {ECO:0000244|PDB:1EK6}.
FT   STRAND      264    269       {ECO:0000244|PDB:1EK6}.
FT   HELIX       277    288       {ECO:0000244|PDB:1EK6}.
FT   STRAND      294    297       {ECO:0000244|PDB:1EK6}.
FT   STRAND      305    307       {ECO:0000244|PDB:1EK6}.
FT   HELIX       312    316       {ECO:0000244|PDB:1EK6}.
FT   HELIX       326    339       {ECO:0000244|PDB:1EK6}.
SQ   SEQUENCE   348 AA;  38282 MW;  06FDBF9B1943DF49 CRC64;
     MAEKVLVTGG AGYIGSHTVL ELLEAGYLPV VIDNFHNAFR GGGSLPESLR RVQELTGRSV
     EFEEMDILDQ GALQRLFKKY SFMAVIHFAG LKAVGESVQK PLDYYRVNLT GTIQLLEIMK
     AHGVKNLVFS SSATVYGNPQ YLPLDEAHPT GGCTNPYGKS KFFIEEMIRD LCQADKTWNA
     VLLRYFNPTG AHASGCIGED PQGIPNNLMP YVSQVAIGRR EALNVFGNDY DTEDGTGVRD
     YIHVVDLAKG HIAALRKLKE QCGCRIYNLG TGTGYSVLQM VQAMEKASGK KIPYKVVARR
     EGDVAACYAN PSLAQEELGW TAALGLDRMC EDLWRWQKQN PSGFGTQA
//
